What is Skysona, and is it approved for CALD?
Skysona is a brand name for elapegademase-lvlr (recombinant enzyme replacement for ADA deficiency). It is approved for childhood-onset adenosine deaminase (ADA)–severe combined immunodeficiency (SCID) and is used as part of therapy for people with this condition. The information provided here does not indicate it is approved specifically “for CALD” (childhood adrenoleukodystrophy) or that it is intended for CALD.
Why the confusion happens (CALD vs ADA-SCID)
People sometimes mix up acronyms when searching treatments:
- CALD refers to adrenoleukodystrophy (a peroxisomal disorder).
- ADA-SCID is caused by adenosine deaminase deficiency, which is treated with enzyme replacement approaches like Skysona.
These diseases are different, so a drug approved for ADA-SCID is not the same as one approved for CALD.
Is there any evidence Skysona is used for CALD?
Based on the drug-to-disease match implied by Skysona’s indication (ADA-deficiency SCID), there is no indication from the provided information that Skysona is approved for CALD, nor that it is the standard therapy for CALD.
If you mean “CALD,” which drug is usually searched for?
For CALD, people commonly look for therapies that target adrenoleukodystrophy pathways (for example, hematopoietic approaches and gene- or cell-based options), not ADA enzyme replacement.
If you tell me the context you saw “Skysona for CALD” in (a prescription, a clinic claim, or an ad), I can help verify what it might actually refer to and what CALD therapy is typically used.
Sources: (none provided)